权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Plasma biomarkers for lung cancer diagnosis

用于肺癌诊断的血浆生物标志物

基本信息

批准号：
10820171
负责人：
Feng Jiang
金额：
$ 32.47万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-17 至 2026-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10820171
关键词：
Address Baltimore Benign Biological Markers Blinded Blood Plasma Volume Cancer Detection Caring Certification Cessation of life Clinic Clinical Clinical Laboratory Improvement Amendments Clinical Research Collaborations Complement Complex Data Development Diagnosis Diagnostic Procedure Diagnostic tests Environment Evaluation Future Growth Healthcare Systems Institutional Review Boards Laboratories Laboratory Research Lung nodule Malignant - descriptor Malignant Neoplasms Malignant neoplasm of lung Maryland Medical Medicare MicroRNAs Morbidity - disease rate Non-Small-Cell Lung Carcinoma Performance Phase Plasma Population Preparation Procedures Process Protocols documentation Quality Control Recommendation Reflex action Reproducibility Resources Reverse Transcription Sampling Scanning Scientist Secure Smoker Specificity Specimen System Target Populations Technology Testing Therapeutic procedure Translating United States Centers for Medicare and Medicaid Services Universities Variant biomarker panel biomarker validation cancer diagnosis cohort computed tomography screening cost design effective therapy follow-up geographically distant laboratory equipment low dose computed tomography lung cancer screening microRNA biomarkers mortality multidisciplinary new technology next generation sequencing performance tests predictive modeling prospective research clinical testing sample collection screening program smoking-related disease success

项目摘要

Project Summary-Abstract Because the early detection of lung cancer by low-dose CT (LDCT) can reduce the mortality, annual LDCT screening is now being reimbursed by Centers for Medicare & Medicaid Services (CMS) for smokers insured through Medicare. However, more than one-quarter of screens discover indeterminate pulmonary nodules (PNs). 4% of PNs are early-stage lung cancers, while the remaining 96% are benign. Therefore, LDCT has over-diagnosis. There is an unmet need for a reflex test for LDCT follow-up to focus care on the 4% smokers need it. The objective of this project is to develop and validate a plasma test for differentiating malignant from benign PNs at baseline LDCT. Future use of this test for discriminating between malignant and benign PNs will complement LDCT for lung cancer detection by reducing the over-diagnosis, and eventually decrease the deaths and cost.

项目摘要-摘要由于低剂量CT（LDCT）早期发现肺癌可以降低死亡率，每年的LDCT筛查现在由医疗保险和医疗补助服务中心报销 (CMS)吸烟者通过医疗保险。超过四分之一的屏幕发现不确定的肺结节（PN）。4%的PN是早期肺癌，而其余96%为良性。因此，LDCT存在过度诊断。的需求尚未得到满足 LDCT随访的反射测试，将重点放在4%的吸烟者需要的护理上。该项目是开发和验证血浆测试，用于区分恶性和良性PN，基线LDCT。将来使用该试验来区分恶性和良性PN，通过减少过度诊断来补充LDCT用于肺癌检测，减少死亡和成本。